CN102659943B - 抗体可变区的糖基化 - Google Patents

抗体可变区的糖基化 Download PDF

Info

Publication number
CN102659943B
CN102659943B CN201210137369.8A CN201210137369A CN102659943B CN 102659943 B CN102659943 B CN 102659943B CN 201210137369 A CN201210137369 A CN 201210137369A CN 102659943 B CN102659943 B CN 102659943B
Authority
CN
China
Prior art keywords
antibody
glycosylated
seq
composition
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201210137369.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102659943A (zh
Inventor
H·洛茨西尔
W·赫伯
D·舒鲍尔
K·魏尔
M·布洛克豪斯
B·宝曼
H·科尔
A·绍布玛
K·兰奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN102659943A publication Critical patent/CN102659943A/zh
Application granted granted Critical
Publication of CN102659943B publication Critical patent/CN102659943B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201210137369.8A 2005-12-12 2006-12-11 抗体可变区的糖基化 Active CN102659943B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027090.9 2005-12-12
EP05027090 2005-12-12
CN2006800463079A CN101351476B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2006800463079A Division CN101351476B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Publications (2)

Publication Number Publication Date
CN102659943A CN102659943A (zh) 2012-09-12
CN102659943B true CN102659943B (zh) 2015-07-01

Family

ID=37745986

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210137369.8A Active CN102659943B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化
CN2006800463079A Active CN101351476B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800463079A Active CN101351476B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Country Status (33)

Country Link
US (2) US8906370B2 (https=)
EP (2) EP1960428B1 (https=)
JP (1) JP5145241B2 (https=)
KR (2) KR20080077132A (https=)
CN (2) CN102659943B (https=)
AR (1) AR057233A1 (https=)
AT (1) ATE517923T1 (https=)
AU (1) AU2006326301B2 (https=)
BR (1) BRPI0619605B8 (https=)
CA (1) CA2632828C (https=)
CR (1) CR10000A (https=)
CY (1) CY1114783T1 (https=)
DK (1) DK1960428T3 (https=)
DO (1) DOP2006000278A (https=)
EC (1) ECSP088524A (https=)
ES (1) ES2368591T3 (https=)
IL (1) IL191004A (https=)
JO (1) JO2824B1 (https=)
MA (1) MA30038B1 (https=)
MY (1) MY155286A (https=)
NO (1) NO346105B1 (https=)
NZ (1) NZ568241A (https=)
PE (3) PE20100684A1 (https=)
PL (1) PL1960428T3 (https=)
PT (1) PT1960428E (https=)
RS (1) RS52004B (https=)
RU (1) RU2438706C2 (https=)
SI (1) SI1960428T1 (https=)
TW (1) TWI382990B (https=)
UA (1) UA99097C2 (https=)
UY (1) UY30003A1 (https=)
WO (1) WO2007068429A1 (https=)
ZA (1) ZA200805038B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
UA99097C2 (ru) * 2005-12-12 2012-07-25 Ф. Хоффманн-Ля Рош Аг Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
ES2473623T3 (es) * 2007-08-20 2014-07-07 Glaxo Group Limited Procedimiento de producción
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
KR101247418B1 (ko) * 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
US8163551B2 (en) * 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
WO2011090720A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
SG10201604104PA (en) * 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
ES2564281T3 (es) * 2012-03-08 2016-03-21 F. Hoffmann-La Roche Ag Formulación de anticuerpos Abeta
RU2711552C2 (ru) * 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
ES2862950T3 (es) * 2012-12-18 2021-10-08 Univ Rockefeller Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
CN105899192B (zh) 2013-11-22 2019-08-13 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
IL257146B2 (en) 2015-08-21 2025-01-01 Hoffmann La Roche Method for reducing host cell proteins by affinity chromatography
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
ES2903156T3 (es) * 2015-10-16 2022-03-31 Hoffmann La Roche Un procedimiento para hacer funcionar un sistema y un sistema
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
EP3427183A1 (en) * 2016-03-10 2019-01-16 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3632421B1 (en) * 2017-05-30 2025-08-13 Morinaga Milk Industry Co., Ltd. Acetic acid and/or an acetic acid salt for use in the treatment of alzheimer-type dementia
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
PE20231556A1 (es) * 2020-11-16 2023-10-03 Hoffmann La Roche Glucoformas de fab ricas en manosa
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114720543B (zh) * 2022-04-06 2026-02-24 苏州大学 一种基于固相糖蛋白t抗原糖肽富集和酶切分析的方法
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
KR20260051039A (ko) 2023-08-09 2026-04-15 에프. 호프만-라 로슈 아게 항-a-베타 단백질 항체, 이의 제조 방법 및 용도
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN117783359B (zh) * 2023-12-28 2024-12-31 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142775A (zh) * 1993-12-08 1997-02-12 免疫医学股份有限公司 免疫结合物的制备和使用
CN1191606A (zh) * 1995-06-06 1998-08-26 干细胞治疗公司 BL3造血干细胞上的糖蛋白gp105
CN101351476B (zh) * 2005-12-12 2013-04-03 豪夫迈·罗氏有限公司 抗体可变区的糖基化

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1161449B1 (en) * 1999-03-04 2007-07-04 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
WO2000077178A1 (en) 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
AU6722300A (en) 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NZ540564A (en) 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005501220A (ja) 2000-12-19 2005-01-13 パラチン テクノロジーズ インク． ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
US7320790B2 (en) 2001-04-30 2008-01-22 Eli Lilly And Company Humanized antibodies
JP2005503789A (ja) * 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
PT1944040E (pt) * 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1142775A (zh) * 1993-12-08 1997-02-12 免疫医学股份有限公司 免疫结合物的制备和使用
CN1191606A (zh) * 1995-06-06 1998-08-26 干细胞治疗公司 BL3造血干细胞上的糖蛋白gp105
CN101351476B (zh) * 2005-12-12 2013-04-03 豪夫迈·罗氏有限公司 抗体可变区的糖基化

Also Published As

Publication number Publication date
CR10000A (es) 2008-07-29
PE20100684A1 (es) 2010-10-04
RU2438706C2 (ru) 2012-01-10
WO2007068429A1 (en) 2007-06-21
AU2006326301B2 (en) 2011-04-21
BRPI0619605A2 (pt) 2011-10-11
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
CN101351476A (zh) 2009-01-21
ES2368591T3 (es) 2011-11-18
ZA200805038B (en) 2009-06-24
EP1960428B1 (en) 2011-07-27
PL1960428T3 (pl) 2012-02-29
JP5145241B2 (ja) 2013-02-13
NZ568241A (en) 2011-08-26
AU2006326301A1 (en) 2007-06-21
CA2632828C (en) 2012-07-10
UY30003A1 (es) 2007-08-31
NO346105B1 (no) 2022-02-21
HK1130066A1 (en) 2009-12-18
US8906370B2 (en) 2014-12-09
ATE517923T1 (de) 2011-08-15
UA99097C2 (ru) 2012-07-25
DOP2006000278A (es) 2007-07-15
BRPI0619605B1 (pt) 2019-08-13
TWI382990B (zh) 2013-01-21
TW200736273A (en) 2007-10-01
EP2377886A1 (en) 2011-10-19
US20150165022A1 (en) 2015-06-18
IL191004A (en) 2013-08-29
US20090252724A1 (en) 2009-10-08
PE20071002A1 (es) 2007-11-19
PE20100748A1 (es) 2010-11-12
KR20120089483A (ko) 2012-08-10
DK1960428T3 (da) 2011-08-22
MA30038B1 (fr) 2008-12-01
RU2008128138A (ru) 2010-01-20
EP1960428A1 (en) 2008-08-27
JO2824B1 (en) 2014-09-15
HK1176075A1 (en) 2013-07-19
JP2009520691A (ja) 2009-05-28
SI1960428T1 (sl) 2011-10-28
ECSP088524A (es) 2008-07-30
MY155286A (en) 2015-09-30
KR20080077132A (ko) 2008-08-21
CN101351476B (zh) 2013-04-03
AR057233A1 (es) 2007-11-21
PT1960428E (pt) 2011-10-07
CN102659943A (zh) 2012-09-12
RS52004B (sr) 2012-04-30
BRPI0619605B8 (pt) 2021-05-25
US9272031B2 (en) 2016-03-01
KR101401159B1 (ko) 2014-05-29
NO20082874L (no) 2008-08-28
CY1114783T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
CN102659943B (zh) 抗体可变区的糖基化
TWI501975B (zh) 針對抗澱粉樣蛋白-β肽之抗體及使用彼等之方法
JP5042828B2 (ja) アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
KR102791519B1 (ko) 미스폴딩된 tdp-43 결합 분자
JP2025094219A (ja) 抗ｔｄｐ－４３結合分子およびその使用
HK1176075B (en) Antibody glycosylation in the variable region
CN101193914B (zh) 抗β-淀粉样肽抗体及其使用方法
MX2008006948A (es) Glicosilacion en la region variable
HK1130066B (en) Antibody glycosylation in the variable region
EP4676596A1 (en) Anti-tdp-43 binding molecules and uses thereof
HK1142613B (en) Methods of treating ophthalmic diseases
HK1142613A (en) Methods of treating ophthalmic diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176075

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1176075

Country of ref document: HK